Teva Divests Takeda JV, Pivots To Innovative Drugs In Japan

Takeda Expects $365m Payment

The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.

(Shutterstock)

Teva is divesting Teva Takeda, its joint venture with Takeda Pharmaceutical in Japan, as it seeks to focus on bringing innovative medicines to the Japanese market.

More from Japan

More from Focus On Asia